Literature DB >> 12522830

Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis.

Guy-Robert Auleley1, Karima Benbouazza, Anneke Spoorenberg, Eduardo Collantes, Najia Hajjaj-Hassouni, Desirée van der Heijde, Maxime Dougados.   

Abstract

OBJECTIVE: To evaluate the smallest detectable difference (SDD) of symptomatic outcome or process variables in ankylosing spondylitis (AS) patients from various countries.
METHODS: Thirty consecutive AS patients with axial involvement were recruited from 1 center in each of 4 countries (Spain, Morocco, France, The Netherlands), for a total of 120 patients. Fourteen variables were studied in 6 domains: pain (3 variables), stiffness (1 variable), function (2 variables), spinal mobility (3 variables), patient global assessment (4 variables), and the domain of enthesiopathy (1 variable). All patients were evaluated twice within a 1-week period during which no clinical or therapeutic change occurred. Intracenter reliability was evaluated using the intraclass correlation coefficient (ICC). The SDD was determined using the Bland-Altman method.
RESULTS: Of the 14 variables evaluated in the 120 patients (82% males, 42 +/- 12 years old, with a mean disease duration of 17 +/- 13 years), only the SDD for the variable occiput-to-wall distance showed statistically significant difference among centers. For the entire group, the SDD, expressed as percentage of the range of the variable, varied from 10% (Mander enthesis index) to 39% (spinal pain at night last week). The intraobserver reliability was good (ICC > 0.80) except for the variables morning stiffness and modified Schober test (ICCs of 0.76 and 0.60, respectively).
CONCLUSION: This study suggests that the evaluation of AS patients is homogenous and reliable in different centers of different European and North African countries. Evaluation of the SDD of the symptomatic outcome or process variables is a starting point to determine the minimum clinically important difference, permitting the presentation of results of clinical studies on an individual basis.

Entities:  

Mesh:

Year:  2002        PMID: 12522830     DOI: 10.1002/art.10798

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

1.  Health-related quality of life in Moroccan patients with ankylosing spondylitis.

Authors:  Yousra Ibn Yacoub; Bouchra Amine; Assia Laatiris; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

2.  Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI).

Authors:  Juan L Garrido-Castro; Alejandro Escudero; Rafael Medina-Carnicer; Alfonso M Galisteo; Cristina Gonzalez-Navas; Loreto Carmona; Eduardo Collantes-Estevez
Journal:  Rheumatol Int       Date:  2013-12-20       Impact factor: 2.631

3.  An exploration of the inter- and intra-rater reliability of the Bath Ankylosing Spondylitis Metrology Index.

Authors:  Jane H Martindale; Chris J Sutton; Lynne Goodacre
Journal:  Clin Rheumatol       Date:  2012-08-15       Impact factor: 2.980

4.  The relationship between enthesitis indices and disease activity parameters in patients with ankylosing spondylitis.

Authors:  Filiz Sivas; Bedriye Mermerci Başkan; Esra Erkol Inal; Lale Akbulut Aktekin; Nurdan Barça; Kürşat Ozoran; Hatice Bodur
Journal:  Clin Rheumatol       Date:  2008-10-24       Impact factor: 2.980

5.  Moving instead of asking? Performance-based tests and BASFI-questionnaire measure different aspects of physical function in ankylosing spondylitis.

Authors:  Salima F E van Weely; J Christiaan van Denderen; Martijn P M Steultjens; Marike van der Leeden; Michael T Nurmohamed; Joost Dekker; Ben A C Dijkmans; Irene E van der Horst-Bruinsma
Journal:  Arthritis Res Ther       Date:  2012-03-08       Impact factor: 5.156

6.  Normative values for the Bath Ankylosing Spondylitis Functional Index in the general population compared with ankylosing spondylitis patients in Morocco.

Authors:  Ghizlane Wariaghli; Fadoua Allali; Kenza Berrada; Zineb Idrissi; Ihsane Hmamouchi; Redouane Abouqal; Najia Hajjaj-Hassouni
Journal:  BMC Musculoskelet Disord       Date:  2012-03-21       Impact factor: 2.362

7.  Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors.

Authors:  Ivette Essers; Astrid van Tubergen; Frank Heldmann; Xenofon Baraliakos; Jürgen Braun; Uta Kiltz; Annelies Boonen
Journal:  RMD Open       Date:  2015-11-17

8.  Inter-rater reliability of clinical mobility measures in ankylosing spondylitis.

Authors:  J Calvo-Gutiérrez; J L Garrido-Castro; C González-Navas; M C Castro-Villegas; R Ortega-Castro; C López-Medina; P Font-Ugalde; A Escudero-Contreras; E Collantes-Estévez
Journal:  BMC Musculoskelet Disord       Date:  2016-09-05       Impact factor: 2.362

9.  Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.

Authors:  Désirée M van der Heijde; Dennis A Revicki; Katherine L Gooch; Robert L Wong; Hartmut Kupper; Neesha Harnam; Chris Thompson; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2009-08-17       Impact factor: 5.156

10.  Measuring disease activity in psoriatic arthritis.

Authors:  Priscilla C H Wong; Ying-Ying Leung; Edmund K Li; Lai-Shan Tam
Journal:  Int J Rheumatol       Date:  2012-12-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.